Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients

BackgroundSodium–glucose co-transporter 2 (SGLT2) inhibitors provide cardiovascular protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However, there is little evidence of their application in patients with chronic kidney disease (CKD). Furthermore, there are incons...

Full description

Bibliographic Details
Main Authors: Xiutian Chen, Jiali Wang, Yongda Lin, Kaijin Yao, Yina Xie, Tianbiao Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Endocrinology
Subjects:
sodium-glucose cotransporter 2(SGLT2) inhibitors
chronic kidney disease (CKD)
randomized controlled trial (RCT)
meta-analysis
cardiovascular
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1236404/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1236404/full

Similar Items